Dr. Mark Baker talked about Medichain, the revolutionary medical data platform he founded
In this interview, founder and CEO of MediChain Medical Big Data Platform, a Blockchain solution for medical data storage and distribution, Dr.. We talked to Mark Baker. The platform gives patients full control over their own medical data and enables the secure exchange of medical records while protecting sensitive data from hackers.. Dr.. Baker has a significant background in cancer research and is also a big data expert.. He believes MediChain is a groundbreaking tool for medical researchers who can access larger data and more comprehensive datasets.
What led you to cancer research in the first place?
Dr.. Mark Baker: I wanted to work in a field that would make a huge impact and make a big difference to the world.. Frankly, cancer is a disease that affects millions of people around the world today and is one of the biggest killers.. I was looking at things where a more systematic, more numerical approach could make a difference to a large number of people, and this is what cancer research looked like.
And how did you start working in data science?
Dr.. Mark Baker: So, that’s really important, the leverage that people have in the world is based on very limited mental tools.. What are these tools? We have things like logic that allow us to make decisions apart from our own feelings.. Math allows us to go beyond what our brain has developed for functioning. Data science, a large-scale application of mathematical science. The great leverage we have is using math and science. Due to the stochastic nature of the data, 19. It was not possible to apply the revolutionary things that took place in the 19th century to physics.. This leads us to a simple answer. We have to approach this in a different way, and how do we do it with data science.
So how did you work in both areas? Did you start with one and then move on to the other? How has this progress been for you?
Dr. Mark Baker: I was into computers when I was nine. My father was an electronics lecturer and gave me access to the mainframe he taught me during summer vacation.. I was too small to reach the computer console, so I was standing on piles of computer paper to get to it.. It was a fully powered IBM mainframe, that’s where I learned. Before going to college, I had a moderately successful attempt at developing a new method of holography.. I then entered Imperial College as a biochemist and then did a master’s in biophysics and bioengineering, which led me to Oxford. I started with algorithms and parallel data processing, which is something new in the pharmaceutical industry, and even designed my own hardware to achieve the processing speeds we need.
Do you have any specific advice to give to your youth? Have you had any regrets?
Dr. Mark Baker: I don’t really regret it. Everything in your path is what makes you you. So who would want to change it? But I would say to my younger self – and I see other young people making the same mistake – when you see an opportunity, you should seize it.. And don’t just follow the traditional lesson.
What inspired you to start the MediChain project?
Dr. Mark Baker: I’ve been thinking about big data for many years with my Oxford colleagues. We’ve been discussing and developing ideas on how to share for some time now, every piece of data needs to be accessible to be digitally signed so we know where it’s coming from, what the sources are. About three years ago the University of Edinburgh reached out to me to start a startup for analytical forecasting using NHS data.. They wanted to know what the best treatments were, what the best practices were, what the hidden negative or positive side effects of drug treatments might be, and what else could be done.. This project didn’t work out but I really formulated how we should use the data and what we’re going to do. Then blockchain came along and it seemed like a natural opportunity.. It had the encrypted cache we mentioned earlier and had a lot of functionality distribution that we needed. And of course a lot of work had been done on the datasets and it was really just about putting them together.. I also had experience with the US healthcare system in San Francisco, and it gave me the impression of how fragmented other healthcare systems are.. So I could see the need for patients in the US to gather their own data, to take control of it.. Of course over the years they have violated people’s privacy and data integrity and I always felt that this could be approached in another way.. As people mature and realize the value of their own data, there will be some value in letting them control it.
I wondered how this project could actually benefit people in developing countries, because at the moment pharmaceutical companies are in countries that can’t afford to develop drugs. not very profitable to invest. People from developing countries could benefit if they could make their data available to pharmaceutical companies because it has monetary value.
Dr.. Mark Baker: That’s a clear problem. We don’t want to have a situation where people think they are selling their data because they are too poor to access healthcare. Still, I think there is an opportunity to revolutionize the system in large and developing countries.. Taking India as an example, a large part of the population owns smartphones and therefore they can directly reap the benefits of big data system.. In the Indian market, each consumer individually has a lower value to a pharmaceutical company, but the market as a whole is another matter.. India’s economy is roughly the size of European countries and will grow larger over time.
Have any doubts arisen in your mind after starting this project?
Dr.. Mark Baker: I think it’s a matter of challenge. I don’t know if there is a doubt. There are dozens of major challenges we have to overcome and a roadmap for doing them.. But it would be unwise to underestimate the extent of these difficulties.. There are many talented people who have put a lot of time and effort into this kind of thing but have not been successful, so we have to make sure we are humble, listen, and try to have people who can help us learn.. The overall difficulty is too great. So we can tear it apart. We can make sure we reduce the risk. But we know the challenges are important.
One final question: What’s next for your master plan?
Dr.. Mark Baker: There are many closely related blockchain projects that could evolve from Medicchain and become subsidiaries if growth opportunities continue to exist in the blockchain world. things like IoT. Things like remote medical services. All this becomes MediChain’s data source, but each deserves its own project. They are natural subsidiaries that will nurture in the same ecosystem – broad collaboration mainly in the medical field.. Because that makes sense.
Disclaimer: This post is a sponsored whitepaper. Uzmancoin has no affiliation with the product or service on this page. Uzmancoin cannot be held responsible for the risks that may arise from the product or service on this page.. What is written here does not constitute a recommendation.